Please enable JavaScript to continue using this application.

Compare $ANVS vs $KLRS | Chartloom

Compare

$ANVS vs $KLRS

Annovis Bio Inc · Kalaris Therapeutics Inc

ANVS

Annovis Bio Inc

KLRS

Kalaris Therapeutics Inc

Compare $ANVS vs $KLRS

Comparing Annovis Bio Inc and Kalaris Therapeutics Inc

ANVSAnnovis Bio Inc

KLRSKalaris Therapeutics Inc

ANVSAnnovis Bio Inc

Market cap

$42M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-66.8%

52W performance

-46.7%

FCF yield

-103.4%

KLRSKalaris Therapeutics Inc

Market cap

$56M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-71.6%

52W performance

-64.2%

FCF yield

-73.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ANVS

KLRS

Detailed metrics comparison

ANVS

Annovis Bio Inc

KLRS

Kalaris Therapeutics Inc

Market Cap

ANVS$42M

KLRS$56M

Enterprise Value

ANVS$23M

KLRS$45M

Price

ANVS$1.21

KLRS$2.36

P/E Ratio

ANVSN/A

KLRSN/A

P/S Ratio

ANVS0.00x

KLRS0.00x

EV/Sales

ANVS0.00x

KLRS0.00x

EV/EBITDA

ANVS0.00x

KLRS0.00x

P/B Ratio

ANVS16.11x

KLRS1.02x

P/FCF Ratio

ANVSN/A

KLRSN/A

EV/FCF

ANVS-0.54x

KLRS-1.09x

PEG Ratio

ANVSN/A

KLRSN/A

Forward P/E (NTM)

ANVSN/A

KLRSN/A

Forward P/S (NTM)

ANVSN/A

KLRSN/A

Revenue (TTM)

ANVS$0

KLRS$0

Revenue Growth (YoY)

ANVSN/A

KLRSN/A

Forward Rev Growth

ANVS507.4%

KLRS180.3%

Gross Margin (TTM)

ANVS0.0%

KLRS0.0%

Operating Margin (TTM)

ANVS0.0%

KLRS0.0%

EBITDA Margin (TTM)

ANVS0.0%

KLRS0.0%

Net Margin (TTM)

ANVS0.0%

KLRS0.0%

FCF Margin (TTM)

ANVSN/A

KLRSN/A

Net Income (TTM)

ANVS$-50M

KLRS$-44M

FCF (TTM)

ANVS$-43M

KLRS$-41M

EPS (TTM)

ANVS-$1.32

KLRS-$1.86

ROE (TTM)

ANVS-31808.0%

KLRS-7171.0%

ROA (TTM)

ANVS-25878.0%

KLRS-4295.0%

ROIC (TTM)

ANVS-31808.0%

KLRS-4719.0%

Cash

ANVS$19M

KLRS$43M

Debt

ANVS$0

KLRS$32M

Net Cash/Debt

ANVS$19M

KLRS$11M

Current Ratio (TTM)

ANVS3.47x

KLRS10.98x

Quick Ratio (TTM)

ANVS2.95x

KLRS10.76x

Debt/Equity (TTM)

ANVS0.00x

KLRS0.56x

Debt/Assets (TTM)

ANVS0.0%

KLRS0.0%

Interest Coverage (TTM)

ANVSN/A

KLRSN/A

Net Debt/EBITDA (TTM)

ANVS0.00x

KLRS0.00x

Beta

ANVS1.32

KLRS0.44

52W Performance

ANVS-46.7%

KLRS-64.2%

YTD Performance

ANVS-66.8%

KLRS-71.6%

% from 52W High

ANVS-78.0%

KLRS-80.1%

% from 52W Low

ANVS16.3%

KLRS0.4%

Asset Turnover (TTM)

ANVS0.00x

KLRS0.00x

FCF Yield (TTM)

ANVS-103.4%

KLRS-73.4%

Earnings Yield (TTM)

ANVS-118.1%

KLRS-78.8%

Dividend Yield (TTM)

ANVSN/A

KLRSN/A

Rule of 40

ANVS0.0

KLRS0.0

EV/GP/RG

ANVSN/A

KLRSN/A

Ticker research

View ANVS research View KLRS research

Metric	ANVS Annovis Bio Inc	KLRS Kalaris Therapeutics Inc
Market & Valuation
Market Cap	$42M	$56M
Enterprise Value	$23M	$45M
Price	$1.21	$2.36
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	16.11x	1.02x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.54x	-1.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	507.4%	180.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-50M	$-44M
FCF (TTM)	$-43M	$-41M
EPS (TTM)	-$1.32	-$1.86
ROE (TTM)	-31808.0%	-7171.0%
ROA (TTM)	-25878.0%	-4295.0%
ROIC (TTM)	-31808.0%	-4719.0%
Financial Health
Cash	$19M	$43M
Debt	$0	$32M
Net Cash/Debt	$19M	$11M
Current Ratio (TTM)	3.47x	10.98x
Quick Ratio (TTM)	2.95x	10.76x
Debt/Equity (TTM)	0.00x	0.56x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.32	0.44
52W Performance	-46.7%	-64.2%
YTD Performance	-66.8%	-71.6%
% from 52W High	-78.0%	-80.1%
% from 52W Low	16.3%	0.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-103.4%	-73.4%
Earnings Yield (TTM)	-118.1%	-78.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ANVS research	View KLRS research

Valuation

P/S Ratio

ANVS

0.00x

KLRS

0.00x

EV/FCF

KLRS

-1.09x

ANVS

-0.54x

Growth & revenue

Forward Revenue Growth

ANVS

507.4%

KLRS

180.3%

Profitability & performance

Gross Margin

ANVS

0.0%

KLRS

0.0%

ROE

KLRS

-7171.0%

ANVS

-31808.0%

FCF Yield %

KLRS

-73.4%

ANVS

-103.4%

52-Week Performance

ANVS

-46.7%

KLRS

-64.2%

Detailed metrics comparison

ANVS

Annovis Bio Inc

KLRS

Kalaris Therapeutics Inc

Market Cap

ANVS$42M

KLRS$56M

Enterprise Value

ANVS$23M

KLRS$45M

Price

ANVS$1.21

KLRS$2.36

P/E Ratio

ANVSN/A

KLRSN/A

P/S Ratio

ANVS0.00x

KLRS0.00x

EV/Sales

ANVS0.00x

KLRS0.00x

EV/EBITDA

ANVS0.00x

KLRS0.00x

P/B Ratio

ANVS16.11x

KLRS1.02x

P/FCF Ratio

ANVSN/A

KLRSN/A

EV/FCF

ANVS-0.54x

KLRS-1.09x

PEG Ratio

ANVSN/A

KLRSN/A

Forward P/E (NTM)

ANVSN/A

KLRSN/A

Forward P/S (NTM)

ANVSN/A

KLRSN/A

Revenue (TTM)

ANVS$0

KLRS$0

Revenue Growth (YoY)

ANVSN/A

KLRSN/A

Forward Rev Growth

ANVS507.4%

KLRS180.3%

Gross Margin (TTM)

ANVS0.0%

KLRS0.0%

Operating Margin (TTM)

ANVS0.0%

KLRS0.0%

EBITDA Margin (TTM)

ANVS0.0%

KLRS0.0%

Net Margin (TTM)

ANVS0.0%

KLRS0.0%

FCF Margin (TTM)

ANVSN/A

KLRSN/A

Net Income (TTM)

ANVS$-50M

KLRS$-44M

FCF (TTM)

ANVS$-43M

KLRS$-41M

EPS (TTM)

ANVS-$1.32

KLRS-$1.86

ROE (TTM)

ANVS-31808.0%

KLRS-7171.0%

ROA (TTM)

ANVS-25878.0%

KLRS-4295.0%

ROIC (TTM)

ANVS-31808.0%

KLRS-4719.0%

Cash

ANVS$19M

KLRS$43M

Debt

ANVS$0

KLRS$32M

Net Cash/Debt

ANVS$19M

KLRS$11M

Current Ratio (TTM)

ANVS3.47x

KLRS10.98x

Quick Ratio (TTM)

ANVS2.95x

KLRS10.76x

Debt/Equity (TTM)

ANVS0.00x

KLRS0.56x

Debt/Assets (TTM)

ANVS0.0%

KLRS0.0%

Interest Coverage (TTM)

ANVSN/A

KLRSN/A

Net Debt/EBITDA (TTM)

ANVS0.00x

KLRS0.00x

Beta

ANVS1.32

KLRS0.44

52W Performance

ANVS-46.7%

KLRS-64.2%

YTD Performance

ANVS-66.8%

KLRS-71.6%

% from 52W High

ANVS-78.0%

KLRS-80.1%

% from 52W Low

ANVS16.3%

KLRS0.4%

Asset Turnover (TTM)

ANVS0.00x

KLRS0.00x

FCF Yield (TTM)

ANVS-103.4%

KLRS-73.4%

Earnings Yield (TTM)

ANVS-118.1%

KLRS-78.8%

Dividend Yield (TTM)

ANVSN/A

KLRSN/A

Rule of 40

ANVS0.0

KLRS0.0

EV/GP/RG

ANVSN/A

KLRSN/A

Ticker research

View ANVS research View KLRS research

Metric	ANVS Annovis Bio Inc	KLRS Kalaris Therapeutics Inc
Market & Valuation
Market Cap	$42M	$56M
Enterprise Value	$23M	$45M
Price	$1.21	$2.36
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	16.11x	1.02x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.54x	-1.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	507.4%	180.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-50M	$-44M
FCF (TTM)	$-43M	$-41M
EPS (TTM)	-$1.32	-$1.86
ROE (TTM)	-31808.0%	-7171.0%
ROA (TTM)	-25878.0%	-4295.0%
ROIC (TTM)	-31808.0%	-4719.0%
Financial Health
Cash	$19M	$43M
Debt	$0	$32M
Net Cash/Debt	$19M	$11M
Current Ratio (TTM)	3.47x	10.98x
Quick Ratio (TTM)	2.95x	10.76x
Debt/Equity (TTM)	0.00x	0.56x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.32	0.44
52W Performance	-46.7%	-64.2%
YTD Performance	-66.8%	-71.6%
% from 52W High	-78.0%	-80.1%
% from 52W Low	16.3%	0.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-103.4%	-73.4%
Earnings Yield (TTM)	-118.1%	-78.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ANVS research	View KLRS research